Encapsulated glucagon-like peptide-1-producing mesenchymal stem cells have a beneficial effect on failing pig hearts

Stem Cells Translational Medicine

Volumn 1, Issue 10, 2012, Pages 759-769

  Wright, Elizabeth J ^a   Farrell, Kelly A ^a   Malik, Nadim ^a   Kassem, Moustapha ^b   Lewis, Andrew L ^c   Wallrapp, Christine ^d   Holt, Cathy M ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^c BIOCOMPATIBLES UK LTD   (United Kingdom)

^d CellMed AG   (Germany)

Author keywords

CellBeads; Cellular therapy; Glp 1; Mesenchymal stem cells; Myocardial infarction; Pig model

Indexed keywords

COLLAGEN; GLUCAGON LIKE PEPTIDE 1; GREEN FLUORESCENT PROTEIN;

ADULT; ANGIOGENESIS; ANIMAL CELL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CATHETERIZATION; CELL ENCAPSULATION; CELL ENGINEERING; CONTROLLED STUDY; HEART INFARCTION SIZE; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE CELL; HEART MUSCLE INJURY; HEART VENTRICLE REMODELING; HISTOLOGY; HUMAN; IMMUNITY; IMMUNOHISTOCHEMISTRY; INFLAMMATION; MALE; MESENCHYMAL STEM CELL; MICROPHOTOGRAPHY; MYOFIBROBLAST; NONHUMAN; NORMAL HUMAN; PATHOLOGY; SWINE; TRANSTHORACIC ECHOCARDIOGRAPHY;

EID: 84876510681     PISSN: 21576564     EISSN: 21576580     Source Type: Journal    
DOI: 10.5966/sctm.2012-0064     Document Type: Article

References (38)

1. Kreymann B, Williams G, Ghatei MA et al. Glucagon-like peptide-1 7-36: A physiological incretin in man. Lancet 1987;2:1300-1304.
2. Nikolaidis LA, Elahi D, Hentosz T et al. Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy. Circulation 2004;110:955-961.
3. Nikolaidis LA, Mankad S, Sokos GG et al. Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation 2004;109:962-965.
4. Poornima I, Brown SB, Bhashyam S et al. Chronic glucagon-like peptide-1 infusion sustains left ventricular systolic function and prolongs survival in the spontaneously hypertensive, heart failure-prone rat. Circ Heart Fail 2008;1:153-160.
5. Sokos GG, Nikolaidis LA, Mankad S et al. Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure. J Card Fail 2006;12:694-699.
6. Zhao T, Parikh P, Bhashyam S et al. Direct effects of glucagon-like peptide-1 on myocardial contractility and glucose uptake in normal and postischemic isolated rat hearts. J Pharmacol Exp Ther 2006;317:1106-1113.
7. Timmers L, Henriques JP, de Kleijn DP et al. Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury. J Am Coll Cardiol 2009; 53:501-510.
8. Sonne D, Engstrom T, Treiman M. Protective effects of GLP-1 analogues exendin-4 and GLP-1 (9-36) amide against ischemia-reperfusion injury in the rat heart. Regul Pept 2008; 146:243-249.
9. Kocher AA, Schuster MD, Szabolcs MJ et al. Neovascularization of ischemic myocardium by human bone-marrow-derived angioblasts prevents cardiomyocyte apoptosis, reduces remodeling and improves cardiac function. Nat Med 2001;7:430-436.
10. Orlic D, Kajstura J, Chimenti S et al. Bone marrow cells regenerate infarcted myocardium. Nature 2001;410:701-705.
11. Hashemi SM, Ghods S, Kolodgie FD et al. A placebo controlled, dose-ranging, safety study of allogenic mesenchymal stem cells injected by endomyocardial delivery after an acute myocardial infarction. Eur Heart J 2008; 29:251-259.
12. Schächinger V, Erbs S, Elsasser A et al. Improved clinical outcome after intracoronary administration of bone-marrow-derived progenitor cells in acute myocardial infarction: Final 1-year results of the REPAIR-AMI trial. Eur Heart J 2006;27:2775-2783.
13. Yousef M, Schannwell CM, Kostering M et al. The BALANCE Study: Clinical benefit and long-term outcome after intracoronary autologous bone marrow cell transplantation in patients with acute myocardial infarction. J Am Coll Cardiol 2009;53:2262-2269.
14. Alaiti MA, Ishikawa M, Costa MA. Bone marrow and circulating stem/progenitor cells for regenerative cardiovascular therapy. Transl Res 2010;156:112-129.
15. Singla DK. Stem cells in the infracted heart. J Cardiovasc Transl Res 2010;3:73-78.
16. Nesselmann C, Ma N, Bieback K et al. Mesenchymal stem cells and cardiac repair. J Cell Mol Med 2008;12:1795-1810.
17. Timmers L, Lim SK, Hoefer IE et al. Human mesenchymal stem cell-conditionedmediumimproves cardiac function following myocardial infarction. Stem Cell Res 2011;6:206-214.
18. Weber C, Pohl S, Poertner R et al. Production process for stem cell based therapeutic implants: Expansion of the production cell line and cultivation of encapsulated cells. Adv Biochem Eng Biotechnol 2010;123:143-162.
19. Glage S, Klinge PM, Miller MC et al. Therapeutic concentrations of glucagon-like peptide- 1 in cerebrospinal fluid following cellbased delivery into the cerebral ventricles of cats. Fluids Barriers CNS 2011;8:18.
20. Heile AM, Wallrapp C, Klinge PM et al. Cerebral transplantation of encapsulated mesenchymal stem cells improves cellular pathology after experimental traumatic brain injury. Neurosci Lett 2009;463:176-181.
21. Klinge PM, Harmening K, Miller MC et al. Encapsulated native and glucagon-like peptide- 1 transfected human mesenchymal stem cells in a transgenic mouse model of Alzheimer's disease. Neurosci Lett 2011;497: 6-10.
22. Zhang R, Zhang H, Xu L et al. Neuroprotective effect of intravitreal cell-based glucagon- like peptide-1 production in the optic nerve crush model. Acta Ophthalmol 2011;89: e320-e326.
23. Houtgraaf JH, Dejong R, Monkhorst K et al. Feasibility of intracoronary GLP-1 eluting CellBeadTM infusion in acute myocardial infarction. Cell Transplant 2012.
24. Simonsen JL, Rosada C, Serakinci N et al. Telomerase expression extends the proliferative life-span and maintains the osteogenic potential of human bone marrow stromal cells. Nat Biotechnol 2002;20:592-596.
25. Cho J, Zhai P, Maejima Y et al. Myocardial injection with GSK-3beta-overexpressing bone marrow-derived mesenchymal stem cells attenuates cardiac dysfunction after myocardial infarction. Circ Res 2011;108:478-489.
26. Passier R, van Laake LW, Mummery CL. Stem-cell-based therapy and lessons from the heart. Nature 2008;453:322-329.
27. Gnecchi M, Zhang Z, Ni A et al. Paracrine mechanisms in adult stem cell signaling and therapy. Circ Res 2008;103:1204-1219.
28. Wolf D, Reinhard A, Seckinger A et al. Regenerative capacity of intravenous autologous, allogeneic and human mesenchymal stem cells in the infarcted pig myocardiumcomplicated by myocardial tumor formation. Scand Cardiovasc J 2009;43:39-45.
29. Breitbach M, Bostani T, Roell W et al. Potential risks of bone marrow cell transplantation into infarcted hearts. Blood 2007;110: 1362-1369.
30. Pfeffer M, Braunwald E. Ventricular remodeling after myocardial infarction. Experimental observations and clinical implications. Circulation 1990;81:1161-1172.
31. Bose AK, Mocanu MM, Carr RD et al. Glucagon like peptide-1 is protective against myocardial ischemia/reperfusion injury when given either as a preconditioning mimetic or at reperfusion in an isolated rat heart model. Cardiovasc Drugs Ther 2005;19: 9-11.
32. Li Y, Hansotia T, Yusta B et al. Glucagonlike peptide-1 receptor signaling modulates beta cell apoptosis. J Biol Chem 2003;278:471-478.
33. Bose AK, Mocanu MM, Carr RD et al. Glucagon- like peptide 1 can directly protect the heart against ischemia/reperfusion injury. Diabetes 2005;54:146-151.
34. Li Z, Guo J, Chang Q et al. Paracrine role for mesenchymal stem cells in acute myocardial infarction. Biol Pharm Bull 2009;32:1343-1346.
35. Ban K, Kim KH, Cho CK et al. Glucagonlike peptide (GLP)-1(9-36)amide-mediated cytoprotection is blocked by exendin(9-39) yet does not require the known GLP-1 receptor. Endocrinology 2010;151:1520-1531.
36. Noyan-Ashraf MH, Momen MA, Ban K et al. GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice. Diabetes 2009;58:975-983.
37. Tang YL, Zhao Q, Qin X et al. Paracrine action enhances the effects of autologous mesenchymal stem cell transplantation on vascular regeneration in rat model of myocardial infarction. Ann Thorac Surg 2005;80:229-236. discussion 236-237.
38. Dokken BB, La Bonte LR, Davis-Gorman G et al. Glucagon-like peptide-1 (GLP-1), immediately prior to reperfusion, decreases neutrophil activation and reduces myocardial infarct size in rodents. Horm Metab Res 2011;43:300-305.